Pure Global AI
NCT05764265Recruiting

Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension Participants

An Open-label Extension Study to Investigate Efficacy, Safety and Tolerability of LTP001 in Participants With Pulmonary Arterial Hypertension
Novartis PharmaceuticalsPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Pulmonary Arterial Hypertension
Drug/Device/Intervention
LTP001
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Novartis Pharmaceuticals
Funder
Novartis
Location
Heidelberg,Wroclaw, Germany,Poland
Timeline & enrollment
Phase
Phase 2
Start date
Mar 27, 2023
End date
Sep 29, 2025
Enrollment
40 participants
Primary outcome

Number of patients with AEs and SAEs

Summary

The purpose of this study is to measure the long-term safety and efficacy profile of LTP001
 in participants with pulmonary arterial hypertension (PAH). The study offers participants who
 had completed the CLTP001A12201 double-blind parent study in PAH an opportunity to receive
 LTP001 (whether they were on LTP001 or not). Unblinding of the treatment received in
 CLTP001A12201 is generally not needed, but can occur on request by the investigator.

ICD-10 classifications
Primary pulmonary hypertensionOther secondary pulmonary hypertensionPulmonary heart disease and diseases of pulmonary circulationStenosis of pulmonary arteryPulmonary heart disease, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05764265
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05764265 through Pure Global AI's free database. This Phase 2 trial is sponsored by Novartis Pharmaceuticals and is currently Recruiting. The study focuses on Pulmonary Arterial Hypertension. Target enrollment is 40 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.